Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Alnylam Pharmaceuticals, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Under Investigation?
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY).
On October 29, 2026, Alnylam reported its financial results for the third quarter ended September 30, 2026. Among other items, the Company reported slowing demand for one of its transthyretin-mediated amyloidosis treatments, Amvuttra, which accounts for 87.5% of Alnylam’s product sales. Alnylam announced U.S. total transthyretin demand growth of $81 million, compared to $129 million for the preceding quarter. Following this news, Alnylam’s stock price fell $58.40, or 25.13%, to close at $174.00 on October 29, 2026.
What Potential Securities Violations Is BG&G Investigating?
- Whether Alnylam Pharmaceuticals, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
- Whether Alnylam Pharmaceuticals, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
- Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.
What Should Alnylam Pharmaceuticals, Inc. (ALNY) Investors Do?
How Is Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Stock Trading Today?
Interactive chart showing the weekly share price history of NASDAQ:ALNY (NASDAQ:ALNY).
How Does BG&G Help Investors in Securities Fraud Investigations?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”